Effectiveness of transarterial embolization of liver neuroendocrine metastases Abstract #133

Introduction: Neuroendocrine tumors (NETs) with diffuse liver metastases have a poor prognosis and prove difficult to palliate. Somatostatin analogues and chemotherapy have been used but often are poorly tolerated and may not provide symptom relief. Transarterial Embolization (TAE) is being increasingly used to improve symptom control and reduce tumor size. We looked at the last 5-year experience of TAE in patients with hepatic metastases from neuroendocrine tumors.
Aim(s): To investigate outcome of patients treated with TAE in the last five years. To look specifically at objective improvement in symptoms and tumor size, including use or RECIST criteria. To look at long-term survival after TAE.
Materials and methods: From our radiology department, we identified all patients who received TAE within the last five years. We used a pre-developed proforma and obtained data from case notes and e-records for: demographics, type of NET, other treatment received including medical therapy and any surgery. We determined the number of TAE treatments per patient, and determined symptoms before and after TAE. We also looked for radiological and biochemical response. We also looked at survival rates. The mean survival time was defined as from time of TAE to date of death or most recent follow-up - December 2009.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Dalvinder S Mandair

To read results and conclusion, please login ...

Further abstracts you may be interested in

#130 Lanreotide Autogel for malignant carcinoid syndrome: an 8-year experience
Introduction: Somatostatin analogues provide symptomatic relief in carcinoid syndrome and recently have been shown to inhibit tumor growth in metastatic gastroenteropancreatic neuroendocrine tumors (NETs). Lanreotide compounds are reported to have similar efficacy to Octreotide compounds. There is limited long-term data available on Lanreoitde Autogel.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#423 Case Report : A Rare Cause of Retroperitoneal Fibrosis Responding to Steroids
Introduction: Retroperitoneal fibrosis is a rare inflammatory disease. Neuroendocrine tumors are a heterogenous group that arise from enterochromaffin cells, most commonly in the gastrointestinal tract. Their capacity to secrete hormones, five HT, tachykinins etc, are responsible for symptoms known as carcinoid syndrome. However NETS, particularly arising from the midgut, can cause fibrosis. This can result in bowel obstruction, but also cause fibrosis in the retroperitoneum, lungs and cardiac valvular fibrosis.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Dalvinder Mandair
Authors: Mandair D, Mangat K, Malaki M, Shah T, ...
#519 Effectiveness of Transarterial Embolization in Neuroendocrine Tumors
Introduction: Neuroendocrine tumors (NETs) with liver metastases have a poor prognosis. Somatostatin analogues and chemotherapy are used with some success. Transarterial Embolization (TAE) is increasingly used to improve symptom control and reduce tumor size.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Dalvinder Mandair
#522 Effects of Transarterial Chemoembolization of Liver Metastases from Neuroendocrine Tumors on Clinical Outcome
Introduction: Trans-catheter arterial chemoembolization (TACE) is a method of treatment of non-resectable liver metastases from neuroendocrine tumors (NET) which provides control of clinical symptoms and tumor growth.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Sanja Ognjanovic
#785 Efficacy of Transarterial Chemoembolization of Liver Metastases from Neuroendocrine Tumors
Introduction: Most patients with neuroendocrine tumors present with liver involvement at the time of diagnosis. Transarterial chemoembolization (TACE) is a method of treatment of non-resectable liver metastases which is effective in the control of symptoms and tumor growth.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: dr Sanja Ognjanovic